Welcome to

KaNDy
Therapeutics

Developing a breakthrough treatment for debilitating Women’s Health conditions

A unique approach

Progressing our unique once daily dual mechanism neurokinin antagonist NT-814 a potential breakthrough treatment of chronic debilitating Women’s Health conditions including post-menopausal vasomotor symptoms (PMVMS). NT-814 has successfully completed a Phase 2a proof of concept study demonstrating its potential to reduce the frequency and severity of PMVMS, and is now being prepared to enter an international Phase 2b study in this anchor indication.

Contact Us

For general, media or partnership enquiries, get in touch with us:

Contact Us
Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt